FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
France Urges Faster AI Push Despite Safety Risks 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Allegro Raises 2026 Outlook as International GMV Surges 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Tabletop particle accelerator could transform medicine and materials science 
Ares Names James Garforth Principal for Asia Direct Lending 
China’s Global Times Slams Anthropic CEO’s AI Slowdown Plan as ‘Cold War’ Strategy 
Add as a preferred source on Google
AstraZeneca's drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows Imfinzi to be used in combination with gemcitabine and cisplatin as a neoadjuvant treatment before surgery. After a procedure called radical cystectomy, Imfinzi will also serve as an adjuvant monotherapy.
This approval marks a major milestone for bladder cancer treatment. Clinical trials have demonstrated that the Imfinzi-based regimen can reduce the risk of death by 25% compared to the standard neoadjuvant chemotherapy followed by radical cystectomy alone. This offers new hope for patients suffering from this aggressive form of cancer.
Imfinzi’s approval for muscle-invasive bladder cancer strengthens AstraZeneca’s position in oncology and offers a promising option for those with limited treatment choices. The combination of Imfinzi with chemotherapy drugs like gemcitabine and cisplatin represents a breakthrough in improving survival rates for these patients.
With this approval, Imfinzi is poised to play a crucial role in the treatment landscape for muscle-invasive bladder cancer, providing doctors with a valuable tool to enhance patient outcomes. This development highlights the continued progress in oncology, particularly in addressing challenging cancers like bladder cancer.
By optimizing the use of Imfinzi, patients can now access a more effective treatment option that offers improved survival rates, marking a pivotal moment in cancer care.
